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Update on Diagnosis and Treatment of Resistant Hypertension
Eduardo Pimenta
Resistant hypertension is an increasingly common medical problem, 
and patients with this condition are at a high risk of cardiovascular 
events. The prevalence of resistant hypertension is unknown, but 
data from clinical trials suggest that 20% to 30% of hypertensive 
individuals may be resistant to antihypertensive treatment. The 
evaluation of these patients is focused on identifying true resistant 
hypertension and contributing and secondary causes of hypertension, 
including hyperaldosteronism, obstructive sleep apnea, chronic 
kidney disease, renal artery stenosis, and pheochromocytoma. 
Treatment includes removal of contributing factors, appropriate 
management of secondary causes, and use of effective multidrug 
regimens. More established approaches, such as low dietary salt 
and mineralocorticoid receptor blockers, and new technologies, 
such as carotid stimulation and renal denervation, have been used 
in the management of patients with resistant hypertension.
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INTRODUCTION
Resistant hypertension is defined as a blood 
pressure (BP) that remains above goal in spite of 
use of 3 antihypertensive medications prescribed at 
optimal dose amounts. According to the Scientific 
Statement for Diagnosis and Treatment of Resistant 
Hypertension published by the American Heart 
Association in 2009, one of the three agents should 
ideally be a diuretic.1 Hypertensive patients whose 
BP is controlled on 4 or more antihypertensive 
medications and patients who have uncontrolled 
BP on regimens of 3 drugs from other classes and 
who do not tolerate diuretics are also considered 
to have resistant hypertension. 
The prevalence of resistant hypertension is 
unknown, but data from clinical trials suggest 
that 20% to 30% of hypertensive individuals may 
be resistant to antihypertensive treatment.2,3 For 
example, in the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT), 34% of participants remained 
with uncontrolled BP despite an average of 2 
antihypertensive medications after approximately 
5 years of follow-up.2 At the end of the ALLHAT, 
27% of participants were controlled on 3 or more 
medications, and overall, 49% of participants were 
controlled on 1 or 2 medications. This means that 
approximately 50% of participants needed 3 or more 
BP medications. However, the real prevalence of 
resistant hypertension may be underestimated in 
the ALLHAT, because patients with a history of 
difficult-to-treat hypertension (defined as 2 or more 
medications to achieve a BP lower than 160/100 
mm Hg) were excluded from the study. 
Factors that predispose to antihypertensive 
t r e a t m e n t  r e s i s t a n c e  i n c l u d e  p o p u l a t i o n 
characteristics, such as increased life expectancy, 
higher obesity rates, and decreased physical activity, 
as well as provider characteristics, including 
inadequate attention to systolic BP elevations 
and the more aggressive BP goals recommended 
by guidelines. Furthermore, contributing factors 
(Table 1) and secondary causes of hypertension are 
more likely to present in patients with resistant 
hypertension (Table 2). All patients confirmed to 
have resistant hypertension should be therefore 
investigated for these secondary causes and, when 
possible, referred to an appropriate specialist.1 
Resistant Hypertension—Pimenta
216 Iranian Journal of Kidney Diseases | Volume 5 | Number 4 | July 2011
The impact of treatment of resistant hypertension 
on cardiovascular morbidity and mortality has not 
been specifically addressed. Furthermore, there are 
few high-quality data comparing cardiovascular risk 
in patients with resistant hypertension with those 
in whom hypertension is more easily controlled. 
However, because cardiovascular risk increases 
linearly and progressively with BP levels and 
that lowering of BP reduce cardiovascular and 
renal morbidity and mortality,4 it is reasonable to 
conclude that patients with resistant hypertension 
are likely to have a higher risk and benefit from 
antihypertensive treatment. 
In the present article we discuss the assessment 
and treatment approaches that have been specifically 
tested in patients with confirmed resistant 
hypertension. 
PSEUDORESISTANCE
Pseudoresistance is defined as factitious lack of 
BP control caused by inaccurate measurement 
of BP, inappropriate drug choices or doses, 
nonadherence to prescribed therapy, or the “white-
coat” effect. Pseudoresistance should be ruled out 
in patients with uncontrolled BP. Identification 
of pseudoresistance avoids overtreatment and 
excessive and expensive evaluation.5 
White-coat effect  and poor adherence to 
prescribed medications are common causes of 
uncontrolled hypertension. White-coat effect is the 
difference between office BP and ambulatory or 
home BP measurements and can be calculated as the 
mean office BP minus mean daytime ambulatory BP. 
Ambulatory and home BP monitoring are important 
methods to evaluate patients with uncontrolled BP 
and to assess true treatment resistance in clinical 
practice. Poor adherence to prescribed medications 
is a common cause of uncontrolled hypertension. 
High cost of treatment, poor relations between 
doctor and patient, complex medical regimens, and 
adverse effects of medical therapy are additional 
causes of poor adherence (Figure 1).6
Clinical inertia, defined as the provider’s failure 
to increase therapy when the treatment goal is 
not reached, is a major contributor to suboptimal 
medical treatment and results in uncontrolled 
hypertension.7 Common causes of clinical inertia 
include lack of knowledge of treatment guidelines, 
underestimation of cardiovascular risk, and the 
use of spurious reasons to avoid intensification 
Figure 1. Consequences of poor adherence.
Contributing Factors
Volume expansion
Excess sodium intake
Volume retention secondary to chronic kidney disease
Inadequate diuretic therapy
Obesity
Exogenous substances
Nonsteroidal anti-inflammatory agents
Oral contraceptives
Alcohol
Corticosteroids
Anabolic steroids
Sympathomimetic agents (nasal decongestants, diet pills, 
and cocaine)
Caffeine
Cyclosporine
Erythropoietin
Chemotherapeutic agents
Antidepressants
Table 1. Contributing Factors and Secondary Causes of 
Resistant Hypertension
Secondary Causes
Primary aldosteronism
Obstructive sleep apnea
Chronic kidney disease
Renal artery stenosis
Pheochromocytoma
Central nervous system tumors
Coarctation of the aorta
Thyroid diseases
Table 2. Secondary Causes of Hypertension
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of therapy, eg, physician perception (without 
patient input) that the patient will not accept more 
medications. 
SECONDARY HYPERTENSION
The prevalence of secondary hypertension is 
higher in patients with resistant hypertension than 
in the general hypertensive population. The most 
common secondary causes of resistant hypertension 
are primary aldosteronism (PA), chronic kidney 
disease, renal artery stenosis, and obstructive 
sleep apnea (OSA). The prevalence of secondary 
hypertension increases with age, mainly due to 
increases in the risk of developing chronic kidney 
disease, OSA, and renal artery stenosis.
Primary Aldosteronism
Primary aldosteronism is the most common 
cause of secondary hypertension and is a frequent 
contributor to treatment resistance. The prevalence 
of PA is greater than previously thought, partially 
because hypokalemia and adrenal tumors are no 
longer necessary criteria for the diagnosis of PA. 
In fact, a substantial proportion of patients with 
PA have normal potassium.8 Multiple studies have 
confirmed a prevalence of PA of approximately 
10% among general hypertensive patients, and the 
prevalence is positively correlated with the severity 
of BP.9 Among untreated patients, the prevalence 
of PA increases with increasing severity of the 
hypertension, from 2% in patients with stage 1 
hypertension to 8% in those with stage 2 hypertension 
and 13% in those with stage 3 hypertension.10 
The prevalence of PA is even higher in patients 
with resistant hypertension, approaching 17% to 
22% in multiple studies (Figure 2).11-14 For example, 
in a prospective study 18 of 88 patients (20%) with 
resistant hypertension referred to the University 
of Alabama at Birmingham were diagnosed with 
PA based on a suppressed plasma renin activity 
(< 1.0 ng/mL/h) and a high 24-hour urinary 
aldosterone excretion (> 12 µg/24 h) during high 
dietary sodium intake (> 200 mEq/24 h).11 The 
prevalence of PA was similar in African-American 
and white patients. Because of its high prevalence 
in this patient group, all patients with resistant 
hypertension, even those with normal potassium 
levels, should be evaluated for PA. 
We have shown that patients with resistant 
hypertension are characterized by higher aldosterone 
levels. In a cross-sectional analysis, 279 consecutive 
patients with resistant hypertension were compared 
to 53 controls (with normotension or hypertension 
controlled on 2 antihypertensive medications and 
less).15 Plasma aldosterone, aldosterone-renin ratio, 
and 24-hour urinary aldosterone were significantly 
higher in patients with resistant hypertension than 
in controls. Patients with resistant hypertension 
had lower levels of plasma renin activity and 
higher levels of brain and atrial natriuretic peptides 
compared to controls, providing the evidence that 
intravascular fluid retention plays an important role 
in hypertension resistant to treatment. It is of note 
that 85% of patients with resistant hypertension 
were on recommended doses of thiazide diuretics.
Aldosterone-renin ratio is considered the 
most rel iable test  for screening of  PA, but 
false-positive and false-negative results may 
occur depending on posture, time of the day, 
salt intake, plasma potassium, and concurrent 
medications.16 Medications such as diuretics, 
angiotensin-converting enzyme (ACE) inhibitors, 
and angiotensin receptor blockers (ARBs) can 
mask the diagnosis of PA by causing false-
negatively low aldosterone-renin ratios. However, 
although interfering medications should be ideally 
stopped before screening for PA, the risk of 
stopping medications in patients with resistant 
hypertension needs to be carefully assessed in 
order to avoid loss of hypertension control. If 
Figure 2. Prevalence of primary aldosteronism among patients 
with resistant hypertension in multiples studies of Birmingham,11 
Seattle,12 Oslo,13 and Prague.14
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aldosterone-renin ratio is positive, PA has to be 
confirmed by fludrocortisone suppression test, 
oral sodium loading, and saline infusion testing 
or captopril challenge test.17 After confirmation 
of PA, lateralization of the source of the excessive 
aldosterone secretion demonstrated by adrenal vein 
sampling is critical to guide the management of 
PA. Unilateral adrenalectomy usually has a major 
beneficial effect in patients with confirmed PA 
and lateralization of aldosterone overproduction 
to one adrenal on adrenal venous sampling, not 
only on hypertension control, but also on quality 
of life, reduction in risk of cardiovascular and 
renal target organ damage and risk of events.17-20
Obstructive Sleep Apnea
Obstructive sleep apnea, which is defined as 
preserved and increased respiratory effort despite 
partial or complete occlusion of the upper airway, 
is a strong and independent risk factor for the 
presence and future development of hypertension 
and cardiovascular diseases.21-25 Cross-sectional 
studies indicate that the severity of OSA is related 
to BP and that hypertension occurring in individuals 
with OSA is more likely to be severe and resistant 
to treatment.21,25,26 In 42 patients with resistant 
hypertension referred to a university center, Logan 
and colleagues found that 83% of participants 
had unsuspected OSA (apnea-hypopnea index 
[AHI] ≥ 10/h).27 The prevalence and severity 
were significantly higher in men than in women 
with resistant hypertension. Furthermore, studies 
have shown that OSA and hyperaldosteronism, 
both highly prevalent in patients with resistant 
hypertension, are related and may interact on a 
pathophysiologic basis.28-30 
Chronic Kidney Disease
Chronic kidney disease is not only a common cause 
of resistant hypertension, but also a consequence of 
poor BP control over time. Fluid retention, excessive 
activation of the renin-angiotensin-aldosterone 
system (RAAS) and concomitant medicines are 
related to treatment resistance in patients with 
impaired kidney function.31
Albuminuria and glomerular filtration rate 
should be assessed in all patients with resistant 
hypertension. Because increases in the serum 
creatinine occurs in a late stage of kidney disease, 
glomerular filtration rate should be estimated by 
the use of the Modification of Diet in Renal Disease 
(MDRD) Study or Cockcroft-Gault equation.32 
Dietary salt reduction plays an important role in 
order to reduce volume expansion in patients with 
chronic kidney disease. Loop diuretics effectively 
reduce volume and facilitate BP control in patients 
with a creatinine clearance lower than 30 mL/
min. Blockade of the RAAS in patients with 
impaired kidney function reduces cardiovacular 
risk, improves BP control, and reduces proteinuria 
and progression to end-stage renal disease.33 
Angiotensin-converting enzyme inhibitors and 
ARBs are indicated in patients with mild to 
severe chronic kidney disease, particularly in the 
presence of microalbominuria or macroalbuminuria. 
Reductions in the glomerular filtration rate can 
occur after starting ACE inhibitors or ARBs. These 
changes are usually limited and transitory and are 
not an indication for cessation of therapy.
Renal Artery Stenosis
Renovascular disease is commonly found 
among patients with resistant hypertension and 
multiple risk factors.34,35 Stenotic lesions are 
largely secondary to atherosclerosis (90%), and 
their prevalence increases with age.36 Renal artery 
stenosis is more common in patients with extrarenal 
atherosclerotic disease.36 Fibromuscular dysplasia 
is present in approximately 10% of cases of renal 
artery stenosis and are more frequent in young 
women. Fibromuscular dysplasia is successfully 
treated with balloon angioplasty.37
Patients with resistant hypertension and known 
atherosclerotic disease, declining kidney function, 
or a history of flash pulmonary edema have an 
increased likelihood of atherosclerotic renal arterial 
disease. These patients have to be evaluated with 
renal artery Doppler ultrasonography, renal 
nuclear medicine scan, computed tomography 
scan, or magnetic resonance angiography of 
the renal arteries. The choice of treatment for 
atherosclerotic renal lesions is controversial due to 
a lack of strong evidence in favor of either medical 
treatment or revascularization for BP control and 
preservation of kidney function.38,39 The renal 
venous-renin ratio study is the only diagnostic 
procedure able to determine renin production of 
each kidney separately and can be of considerable 
assistance in treatment decision making. It predicts 
improvement of hypertension after nephrectomy 
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in patients suspected of having unilateral renal 
renin hypersecretion associated with ipsilateral 
marked or complete loss of kidney function.40-42 
Pheochromocytoma
Although the prevalence of pheochromocytoma 
in general hypertensive population is low (0.1% to 
0.6%),43,44 the diagnosis and treatment are extremely 
important due to difficult-to-control hypertension, 
the possibility of precipitating hypertensive crisis 
if the tumor is stimulated, and the possibility 
that the tumor could be malignant.45 The clinical 
presentation of pheochromocytoma is widely 
variable, but the triad of headache, palpitations, 
and sweating are the most common findings.46 All 
patients with resistant hypertension and symptoms 
typical of pheochromocytoma should be screened. 
Plasma free metanephrines are the best screening 
test for pheochromocytoma, with high sensitivity 
(99%) and specificity (89%).47 Surgical removal of 
the tumor is the appropriate treatment.
TREATMENT
Salt Reduction
Sodium causes target organ-damage not only 
through hemodynamic mechanisms, ie, BP, but also 
through nonhemodynamic mechanisms. Dietary 
salt intake induces a complex series of events in 
the endothelium that appear to be independent of 
BP and the RAAS.48 
Observational  studies and cl inical  tr ials 
performed in general and hypertensive populations 
indicate that a high dietary salt intake is associated 
with higher BP. For example, in the INTERSALT 
study, a multinational evaluation that included 
more than 10 000 normotensive and hypertensive 
participants from 52 populations, differences in 
dietary sodium ingestion of 100 mmol per day 
were associated with differences in systolic BP of 
approximately 2.2 mm Hg after adjustment for age, 
sex, potassium excretion, body mass index, and 
alcohol intake.49 The positive relation between salt 
ingestion and level of BP appeared to be stronger 
in patients with hypertension. Meta-analyses have 
suggested that low-salt intervention in hypertensive 
patients decreases systolic and diastolic BP by 
3.7 mm Hg to 7.0 mm Hg and 0.9 mm Hg to 2.5 
mm Hg, respectively.50-52 
Although the effects of reducing dietary sodium 
intake on BP levels have been evaluated in the 
general hypertensive population, few studies have 
examined the role of dietary salt in patients with 
resistant hypertension per se. In one study, 16 
patients with “refractory” hypertension, defined 
as uncontrolled BP on maximum doses of at least 
1 diuretic and 1 sympatholytic agent, were treated 
with extreme dietary salt restriction (10 mmol 
of sodium per day) in combination with intense 
diuretic therapy (either hydrochlorothiazide 100 
mg or furosemide 80 mg to 200 mg daily) after 
ceasing other antihypertensive therapy.53 Systolic 
and diastolic BP decreased on average by 21 mm 
Hg and 7 mm Hg, respectively. However, this 
study had limited practical implications, because 
the definition of refractory hypertension differs 
from the current definition and such extreme 
sodium restriction (< 1.0 g of salt) would be almost 
impossible in the real life without home delivery 
of specially prepared meals. Furthermore, the 
study did not assess the effects of low-salt diet in 
combination with other antihypertensive therapies.
More recently, we published the results of 
a 4-week randomized cross-over study which 
included 12 patients with resistant hypertension.54 
Participants were on an average of 3.4 ± 0.5 
medications, and all the patients were on a thiazide 
diuretic (hydrochlorothiazide, 25 mg/d) and 
an ACE inhibitor or an ARB. Participants were 
randomized to low- or high-salt diet for 1 week 
and crossed over to the opposite diet for 1 week 
after 2 weeks of wash out. Patients remained on 
the same antihypertensive treatment throughout 
the study. The low-salt meals were designed by 
nutritionists on individual basis in order to provide 
50 mmol of sodium per day (2.8 g of salt). During 
the high-salt diet, patients received more than 250 
mmol/d of sodium (14.3 g of salt). Adherence to 
diet was confirmed by measurement of 24-hour 
urinary sodium excretion. The mean office systolic 
and diastolic BP reduced by 22.7/9.1 mm Hg during 
low- compared to high-salt diets. Low-salt diet 
decreased daytime, nighttime, and 24-hour systolic 
and diastolic BP to a similar degree to office BP, 
when compared to high-salt ingestion. The effect 
of low-salt diet on ambulatory BP was persistent 
throughout the 24-hour period (Figure 3). The BP 
reduction achieved during the low-salt ingestion 
was estimated as being equivalent to adding 
2 antihypertensive medications.55 Considering 
BP reductions that have been observed in our 
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study compared to clinical trials with unselected 
and untreated hypertensive subjects, our study 
suggested that patients with resistant hypertension 
are particularly salt sensitive.55
In our study, plasma renin activity increased 
and brain natriuretic peptide, body weight, and 
creatinine clearance decreased significantly with 
low-salt compared to high-salt diet, suggesting 
intravascular fluid retention with high-salt diet. 
It is of note that intravascular fluid retention was 
observed in spite of the use of conventional diuretic 
therapy (hydrochlorothiazide, 25 mg/d). 
Continuous Positive Airway Pressure
Continuous positive airway pressure (CPAP), 
which is used for treatment of OSA, has minimal 
BP effect.56-58 However, CPAP treatment seems to 
have greater antihypertensive effect in patients 
with more severe hypertension. For example, in 
a retrospective study, effects of CPAP therapy on 
BP were assessed in patients with OSA (AHI > 5 
events per hour) and hypertension.59 After 1 year 
of follow-up, treatment with CPAP significantly 
reduced mean arterial pressure in patients with 
resistant hypertension, but not in patients with 
controlled hypertension. In a different study, 64 
patients with resistant hypertension and OSA 
(AHI > 15 events per hour) were randomized to 
treatment with CPAP added to conventional medical 
treatment or conventional treatment alone for 3 
months.60 Reduction in 24-hour diastolic BP was 
significantly greater in patients with confirmed 
resistant hypertension (office BP > 140/90 mm Hg 
and 24-hour BP > 125/80 mm Hg) treated with 
CPAP compared to those treated with conventional 
treatment (-4.9 ± 6.4 versus 0.1 ± 7.3 mm Hg, 
P = .03). Reductions in daytime diastolic, 24-hour 
diastolic and systolic BP were also significantly 
greater among patients who used CPAP more 
than 5.8 hours per night. These results suggest 
that OSA should be investigated in patients with 
resistant hypertension, and CPAP therapy is 
recommended for those with OSA. However, more 
studies are necessary to confirm the CPAP effects 
on BP reduction.
Aldosterone Receptor Blockers
The addition of low doses of mineralocorticoid 
Figure 3. Comparison of 24-hour ambulatory blood pressure values during low- and high-salt diet. Data are presented as mean ± 
standard error. Adapted from a study published in 2009 by Pimenta and colleagues.54
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receptor blockers to the current treatment effectively 
reduces BP in patients with resistant hypertension 
(Figure 4).61-67 In a prospective study, patients with 
resistant hypertension received spironolactone (12.5 
mg/d to 25 mg/d) in addition to their current 
treatment which included an ACE inhibitor or 
ARB and a diuretic.63 Systolic and diastolic BP 
reduced by 25 mm Hg and 12 mm Hg, respectively, 
after 6 months of treatment. There was a similar 
BP reduction in patients with compared to those 
without PA. Furthermore, BP reduction was not 
predicted by baseline plasma aldosterone or renin 
levels or by 24-hour urinary aldosterone, and BP 
reduction was similar in African-American and 
white participants. In the Anglo-Scandinavian 
Cardiac Outcomes Trial-Blood Pressure Lowering 
Arm (ASCOT), 1411 participants who finished the 
study and BP had uncontrolled on 3 antihypertensive 
agents received spironolactone (mean dose, 25 mg) 
as a fourth drug.64 Systolic and diastolic BP reduced 
by 21.9 mm Hg and 9.5 mm Hg, respectively, after 
an average of 1.3 years, independently of age, sex, 
smoking, and diabetes status.
T h e  a b o v e  r e s u l t s  r a i s e d  t h e  q u e s t i o n 
whether the dual blockade of the RAAS with 
spironolactone in combination with an ACE or 
ARB is more effective than dual blockade with 
an ACE inhibitor and an ARB. In a prospective 
open-label crossover study, 42 patients with true 
resistant hypertension (determined by ambulatory 
BP monitoring) received an ACE inhibitor for 12 
weeks in addition to their treatment, if they were 
already being treated with an ARB, or an ARB, if 
they were being treated with an ACE inhibitor.68 
After 4 weeks of washout without the added 
RAAS blocker, patients received spironolactone, 
25 mg, for 12 weeks in addition to their current 
treatment. Spironolactone was increased to 50 mg 
after 4 weeks if necessary. The combination of an 
ACE inhibitor with an ARB reduced office BP by 
12.9/2.2 mm Hg and 24-hour BP by 7.1/3.4 mm 
Hg. In contrast, the addition of spironolactone 
reduced office and 24-hour BP by 32.2/10.9 mm 
Hg and 20.8/8.8 mm Hg, respectively. The study 
not only showed the small BP effect of combining 
ACE inhibitor and ARB, but also confirmed that 
spironolactone should be considered in all patients 
with uncontrolled hypertension on three or more 
antihypertensive agents.69 
Spironolactone, in addition to the lowering 
BP effect, seems to reduce the severity of OSA 
in patients with resistant hypertension. In a 
prospective open-label study, 12 patients with 
resistant hypertension and OSA, defined as AHI of 
15 events per hour or higher, had spironolactone 
added to their current antihypertensive treatment 
for 8 weeks when polysomnography was repeated.70 
Apnea-hypopnea index, hypoxic index, weight, and 
clinical and ambulatory BP significantly reduced, 
and plasma renin activity significantly increased 
after treatment. These results support the concept 
that aldosterone-mediated chronic fluid retention 
may influence severity of OSA.
Eplerenone, a more selective mineralocorticoid 
receptor blocker, also effectively reduces BP in 
patients with resistant hypertension. In an open-
Figure 4. Spironolactone-induced blood pressure reductions observed in studies of patients with resistant hypertension.61-64,66 Adapted 
from a review published in 2007 by Pimenta and colleagues.65
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label non-placebo-controlled study, 52 patients 
with resistant hypertension received 50 mg to 100 
mg of eplerenone daily for 12 weeks.71 Eplerenone 
reduced clinic and 24-hour BP by 17.6/7.9 mm Hg 
and 12.2/6.0 mm Hg, respectively. Similar to the 
studies with spironolactone, BP reductions were 
weakly related to baseline serum aldosterone and 
unrelated to plasma renin activity, age, gender, 
or race. 
Spironolactone at the studied doses (12.5 mg to 
50 mg) is usually well tolerated even in combination 
with ACE inhibitors or ARBs. Serum potassium and 
creatinine levels should be monitored in patients 
treated with mineralocorticoid receptor antagonists. 
Potassium supplementation or salt substitutes 
that contain potassium should be discontinued 
or reduced in patients who are started on these 
agents. Spironolactone-associated hyperkalemia 
is uncommon in patients with normal kidney 
function, but risk of hyperkalemia is increased in 
older patients, in patients receiving ACE inhibitors 
or ARBs and/or non-steroidal anti-inflammatory 
drugs, and in patients with chronic kidney disease 
or diabetes mellitus. In these higher-risk patients, 
spironolactone can be started at 12.5 mg daily. 
Breast tenderness with or without gynecomastia, 
occurs  in  less  than  10% of  men who take 
spironolactone, 25 mg daily, and its occurrence 
increases sharply with higher doses.63,64 The more 
selective mineralocorticoid receptor antagonist 
eplerenone has lower affinity for progesterone 
and androgen receptors and is better tolerated 
than spironolactone.72 
Amiloride, which antagonizes aldosterone 
action by blocking the epithelial sodium channel, 
has been demonstrated to effectively reduce BP 
in patients with aldosterone-related hypertension. 
However, there is less experience using it to 
specifically treat resistant hypertension.13,73 Like 
direct mineralocorticoid receptor antagonists, there 
is a risk of hyperkalemia. 
FUTURE PERSPECTIVES
Endothelin Receptor Blockers
Endothelin, which has been recognized as 
a potent vasoconstrictor factor,  modulates 
cardiovascular function, and stimulation of 
endothelin receptors in the vascular system 
produces marked sustained hypertension.74 
Furthermore, endothelin administration results in 
renal vasoconstriction associated to a decrease in 
sodium excretion.75 The endothelin receptor type 
A is widely expressed and is the main receptor 
of the endothelin system in the vascular smooth 
muscle.76 Because plasma endothelin levels have 
been related to severity of hypertension, endothelin 
antagonists have been tested in patients with 
resistant hypertension. 
A randomized double-blinded placebo-controlled 
trial (DORADO) tested darusentan, a selective 
endothelin type A receptor antagonist, in 379 
patients with resistant hypertension who were 
receiving at least 3 antihypertensive medications 
including a diuretic.77 Participants received placebo 
or darusentan, 50 mg, 100 mg, or 300 mg, for 14 
weeks. Clinic systolic and diastolic BP were reduced 
by 9 ± 14 mm Hg and 5 ± 8 mm Hg, 17 ± 15 mm Hg 
and 10 ± 9 mm Hg, 18 ± 16 mm Hg and 10 ± 9 mm 
Hg, and 18 ± 18 mm Hg and 11 ± 10 mm Hg with 
placebo and darusentan at doses of 50 mg, 100 mg, 
and 300 mg, respectively (P < .001 for all the three 
darusentan doses compared to placebo). There were 
no significant differences between darusentan dose 
groups. In a different study, patients with resistant 
hypertension who had been treated with at least 3 
antihypertensive agents, including a diuretic, were 
randomly assigned to receive darusentan, central 
α2-agonist guanfacine or placebo for 14 weeks.78 
Office systolic BP reduction with darusentan was 
significantly greater than that with guanfacine 
(15 ± 14 mm Hg versus 12 ± 13 mm Hg, P < .05), but 
not greater with placebo (14 ± 14 mm Hg). However, 
24-hour systolic BP reduction with darusentan 
(9 ± 12 mm Hg) was significantly higher than that 
with guanfacine (4 ± 12 mm Hg) or placebo (2 ± 12 
mm Hg). In both studies, adverse effects related 
to fluid retention occurred in approximately 30% 
of patients treated with darusentan despite the 
use of diuretics.77,78 One study reported modest 
increases in serum creatinine and decreases in 
estimated glomerular filtration rate with 100 mg 
and 300 mg of darusentan.77
The endothelin type A receptor antagonist 
darusentan seems to be effective in the treatment 
of resistant hypertension, but volume retention and 
exacerbation of heart failure, in spite of diuretic 
use, occur in almost one-third of patients. More 
data on BP, as well as hypertension-related target-
organ damage and cardiovascular events, and more 
safety data are needed before endothelin type A 
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receptor antagonist can be employed in the routine 
treatment of patients with resistant hypertension.
Baroreflex Activation
The carotid sinus is an important modulator of 
autonomic tone and regulates BP. The brain receives 
signals from the baroreceptors through afferent 
nerves, which subsequently reduces sympathetic 
outflow and BP. Clinical and experimental studies 
have demonstrated that electrical stimulation of 
carotid artery reduces BP.79-83 However, electrical 
carotid sinus nerve stimulation in humans did 
present some limitations such as reduced long-
term effect, unknown amount of stimulation 
required and size of the device, and orthostatic 
hypotension. Also, the development of new and 
effective antihypertensive medications prevented 
the development of new devices for some time.
A new implantable pulse generator, which is 
implanted in the chest similarly to a pacemaker, has 
been tested in patients with resistant hypertension. 
This device has leads that tunnel subcutaneously 
and are bilaterally attached to the carotid sinuses. 
In a nonrandomized prospective feasibility study 
designed to assess safety and efficacy of the pulse 
generator, 45 patients with resistant hypertension 
with baseline mean BP of 179/105 mm Hg on 
a median of 5 antihypertensive medications, 
received the device.84 Only 37, 26, and 17 patients 
completed the 3-month, 1-year, and 2-year follow-
up, respectively. For these time points, office BP 
was reduced by 21/12 mm Hg, 30/20 mm Hg, and 
33/22 mm Hg, respectively. The mean 24-hour 
ambulatory BP was reduced by 6/4 mm Hg, 13/8 
mm Hg, and 24/13 mm Hg for the same periods. 
One patient died 6 days after operation due to 
angioneurotic edema before device activation. 
Other serious adverse events included preoperative 
stroke, infection, generator dislocation, tongue 
paresis (likely due to hypoglossal nerve injury), 
and moderate pulmonary edema. Complications 
related to surgery are the major limitations to 
carotid stimulation despite overall good results. 
Furthermore, BP responses to baroreflex activation 
are largely variable with some patients not 
demonstrating any BP reduction at all. 
Renal Denervation
The sympathetic nervous system is an important 
contributory mechanism in both acute and 
chronic BP pressure elevation. Radical surgical 
procedures, such as thoracic, abdominal, or 
pelvic sympathectomy, effectively reduced BP in 
patients with malignant hypertension. However, 
these procedures were associated with high rates 
of short-term and long-term complications.85-88 
Surgical renal denervation effectively reduces BP, 
which suggests that the sympathetic outflow to 
the kidneys is activated in patients with essential 
hypertension and other diseases that present with 
sympathetic system overactivity, such as congestive 
heart failure.89,90 
These findings have stimulated novel treatments 
such as percutaneous catheter-based radiofrequency 
ablation of the afferent and efferent renal nerves, 
which lie in the wall of the renal artery.91 In a 
safety and proof-of-principle study, 45 patients 
with resistant hypertension underwent renal 
sympathetic denervation through percutaneous 
radiofrequency ablation. Office BP was reduced 
by 14/10 mm Hg, 21/10 mm Hg, 22/1 mm Hg, 
24/11 mm Hg, and 27/17 mm Hg after 1, 3, 6, 
9, and 12 months of follow-up, respectively. 
Renal noradrenaline spillover was measured in 
10 patients and was reduced by a mean of 47%. 
Periprocedure complications included renal artery 
dissection related to the catheter placement before 
delivery of radiofrequency energy in 1 patient and 
development of pseudo-aneurism of the femoral 
artery in another patient. Renal angiography was 
repeated 14 to 18 days after renal sympathetic 
ablation in 14 patients and showed no evidence of 
renal artery stenosis. Magnetic resonance imaging 
performed after 6 months in 14 patients showed 
a nonobstructive lesion in an untreated location 
in 1 patient.91
In the Simplicity HTN-2 Trial, 106 patients with 
resistant hypertension (baseline BP of 178/97 
mm Hg on 5.2 antihypertensive medications) 
were  randomized to  renal  denervat ion or 
medical treatment.92 Change to baseline doses of 
antihypertensive medications were not allowed 
in any of the groups, unless judged medically 
necessary due to signs and symptoms related to 
BP elevation. Clinic BP reduced by 32/12 mm Hg 
(P < .001 both for systolic and diastolic) 6 months 
after renal denervation and by 1/0 mm Hg in the 
control group. Ambulatory BP monitoring data was 
available for 32 patients and showed a 24-hour BP 
reduction of 11/7 mm Hg. 
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Renal  sympathet ic  denervat ion through 
percutaneous radiofrequency is a potentially major 
new addition to the range of treatment for patients 
with poorly controlled hypertension. Furthermore, 
these studies have provided interesting new 
information and opened up new avenues of 
exploration regarding the role of renal sympathetic 
activity in BP regulation and the development of 
essential hypertension. Further studies are needed 
to address the long-term effects of renal denervation 
and its safety and effectiveness in other disease 
states such as congestive heart failure.
CONCLUSIONS
Resistant hypertension is an increasingly common 
medical problem and patients with this condition 
are at a high risk of cardiovascular events. Because 
secondary hypertension may be the underlying 
cause of resistant hypertension, and sometimes 
a specific and definite treatment is available, a 
thorough investigation is mandatory in patients with 
resistant hypertension. However, in the majority 
of these patients, an underlying cause cannot be 
found. More established approaches, such as low 
dietary salt and mineralocorticoid receptor blockers 
are indicated for these patients. New technologies, 
such as carotid stimulation and renal denervation, 
may be used in the near future in the management 
of patients with resistant hypertension.
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